MTAP Loss and Pleural Mesothelioma (PM): Current Treatment Strategies and Emerging Therapeutic Approaches

PM is a locally aggressive tumor associated with asbestos exposure. Despite legislative efforts to regulate asbestos use, its incidence continues to rise in some parts of the world. Chemotherapy and immunotherapy have improved survival in PM patients, but overall survival remains poor. MTAP loss is frequent in PM and may influence tumor behavior, resulting in a poorer prognosis. MTAP-deficient tumors exhibit unique metabolic vulnerabilities that have stimulated the development of targeted therapeutic strategies in recent years with promising results. The aim of this review is to analyze the prognostic and predictive value of MTAP in PM patients, as well as the outcomes of drugs with potential activity against this target.